|1.||Ma, Yinfa: 1 article (01/2011)|
|2.||Gibbons, Stephen: 1 article (01/2011)|
|3.||Gamagedara, Sanjeewa: 1 article (01/2011)|
07/01/1982 - "In our earlier study it was shown that patients with various types of cancer excrete three- to 20-fold higher levels of urinary 6-hydroxymethylpterin as compared to patients with nonmalignant diseases or normal volunteers. "
04/15/1983 - "These results again conclusively show that the simple noninvasive determination of 6-hydroxymethylpterin provides a reliable index of the total tumor load in acute lymphoblastic leukemic cases undergoing treatment."
10/01/1981 - "While 30 healthy human subjects excreted 6-hydroxymethylpterin at a mean levels of 0.121 microgram/ml of urine, 120 patients with various types of cancer excreted vary significantly higher levels ranging from 0.3 to 2.0 microgram/ml. The mean excretion level for 19 patients with various nonmalignant diseases was 0.134 microgram/ml which was not significantly different from that for the healthy control subjects. "
10/01/1981 - "Elevated urinary levels of 6-hydroxymethylpterin during malignancy of liver regeneration: a simple, noninvasive test for cancer detection."
01/14/2011 - "Among the eight pteridines studied, 6-biopterin, 6-hydroxymethylpterin, pterin, xanthopterin, and isoxanthopterin levels were significantly higher in samples from cancer patients than in those from healthy subjects. "
|2.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
04/15/1983 - "In this study, the excreted urinary levels of 6-hydroxymethylpterin as well as the bone marrow lymphoblast values were measured simultaneously in four patients with acute lymphoblastic leukemia (ALL) during antileukemic therapy. "
04/15/1983 - "Urinary 6-hydroxymethylpterin levels accurately monitor response to chemotherapy in acute lymphoblastic leukemia."
07/01/1982 - "The data conclusively show that the simple noninvasive determination of urinary 6-hydroxymethylpterin levels accurately and rapidly reflects the status of the disease under treatment and could conveniently be employed as a suitable index for monitoring the effect of chemotherapy as well as the condition of the residual extramedullary leukemic infiltration."
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|1.||Drug Therapy (Chemotherapy)